A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease

Akiko Hori, Yoshinobu Kanda, Susumu Goyama, Yasushi Onishi, Yukiko Komeno, Kinuko Mitani, Yukiko Kishi, Seishi Ogawa, Osamu Imataki, Shigeru Chiba, Rie Kojima, Tamae Hamaki, Michiyo Sakiyama, Masahiro Kami, Atsushi Makimoto, Ryuji Tanosaki, Yoichi Takaue, Hisamaru Hirai

研究成果: Article

29 引用 (Scopus)

抜粋

This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th) 1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.

元の言語English
ページ(範囲)372-374
ページ数3
ジャーナルTransplantation
79
発行部数3
DOI
出版物ステータスPublished - 2005 2 15
外部発表Yes

ASJC Scopus subject areas

  • Transplantation

フィンガープリント A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Hori, A., Kanda, Y., Goyama, S., Onishi, Y., Komeno, Y., Mitani, K., Kishi, Y., Ogawa, S., Imataki, O., Chiba, S., Kojima, R., Hamaki, T., Sakiyama, M., Kami, M., Makimoto, A., Tanosaki, R., Takaue, Y., & Hirai, H. (2005). A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation, 79(3), 372-374. https://doi.org/10.1097/01.TP.0000151001.64189.1D